BMJ Open

Study protocol to determine the effects of highly absorbable oral curcumin on the indicators of cognitive functioning: a double-blind randomised controlled trial

Maki Komiyama,1 Yuka Ozaki ,1 Hiromichi Wada,1 Hajime Yamakage,1 Noriko Satoh-Asahara,1 Atsuhiko Kishimoto,2 Yasuhiro Katsuura,2 Atsushi Imaiizumi,2 Tadashi Hashimoto,2 Yoichi Sunagawa,3 Tatsuya Morimoto,3 Koji Hasegawa1

To cite: Komiyama M, Ozaki Y, Wada H, et al. BMJ Open 2022;12:e057936. doi:10.1136/bmjopen-2021-057936

ABSTRACT

Introduction Mild cognitive impairment (MCI) refers to a state in which cognitive functions, such as memory, have diminished but daily activities are largely unhampered. MCI is often overlooked but carries the risk of leading to development of dementia later. Curcumin is the main component of the natural herbal medicine turmeric. Curcumin is widely used as a health food and is an antioxidant that has anti-inflammatory and anti-amyloid actions. The current trial was designed to determine the effects of curcumin on indicators of cognitive functioning.

Methods and analysis The current trial will be a single-centre randomised placebo-controlled double-blind parallel group trial. The participants will be 60 members of the general public with potential MCI, based on dementia screening using the Japanese version of the Mini Mental State Examination scores and dementia-associated blood biomarkers.

STRENGTHS AND LIMITATIONS OF THIS STUDY

⇒ The current trial will be a single-centre randomised placebo-controlled double-blind parallel group trial.
⇒ This trial will investigate the effects of a newly developed preparation of a highly absorbable oral curcumin on indicators of cognitive functioning.
⇒ The aim of this trial will be to analyse the outcome of administering highly absorbable oral curcumin (brand name: curcuRouge) in members of the general public suspected of having mild cognitive impairment, in terms of its safety and its effects on the Japanese version of the Mini Mental State Examination scores and dementia-associated blood biomarkers.
⇒ The target sample size will be 60 participants (30 administered with placebo and 30 with the highly absorbable curcumin).

INTRODUCTION

Background of the condition of interest Mild cognitive impairment (MCI) is a state in which individuals exhibit neither dementia nor normal cognitive functioning. Approximately 10% of individuals with MCI will eventually develop Alzheimer’s disease or some other types of dementia. Studies conducted in
The period of MCI is considered to be a precursor to the onset of dementia, and a time when some cognitive functions, although not dementia, have declined and the risk of developing the disease has increased. It is important to take appropriate measures to reduce the risk of developing dementia during the MCI period.3

Cholinesterase inhibitors have been used to treat dementia. In 2005, one such cholinesterase inhibitor, donepezil hydrochloride, was reported to be effective in treating MCI. While donepezil hydrochloride prevented the onset of dementia in the first year, it did not inhibit the subsequent progression of MCI to dementia.4 So far, there is no scientific evidence indicating that donepezil hydrochloride inhibits the progression of MCI to dementia. Therefore, the active administration of cholinesterase inhibitors to treat MCI is not recommended. Lifestyle-related diseases such as hypertension, dyslipidaemia and diabetes are risk factors for MCI.3 A search for the last 5 years of systematic review, meta-analysis and randomised clinical research using 16 keywords such as “dementia”, “cognitive impairment”, “exercise” and “nutrition” suggested that exercise as well as dietary/nutritional interventions and multifaceted interventions for risk factors for angiopathy are effective.5

**Curcumin: previous research**

Curcumin is known to have physiological actions such as anti-tumour, anti-amyloid, anti-inflammatory and antioxidant activities.6 7 The authors demonstrated that the oral administration of curcumin inhibited the progression of heart failure in two rat models of chronic heart failure (hypertensive heart disease and myocardial infarction),8 and these results were reported by the media worldwide, including Columbia Broadcasting System (a major broadcaster in the USA). In a trial involving patients with hypertensive cardiac hypertrophy, the patients were administered a highly absorbable curcumin for 24 weeks, and echocardiography was used to evaluate the left ventricular function. The results indicated that the indicators of left ventricular diastolic function improved significantly. A patent application and another study indicated that a highly absorbable oral curcumin consumed by patients with mild chronic obstructive pulmonary diseases (COPDs) reduced the α1-antitrypsin–low-density lipoprotein complex (AT-LDL) (an oxidised LDL) significantly compared with a placebo.9 10

Curcumin inhibited amyloid deposition in animal experiments; therefore, it is expected to be effective in treating Alzheimer’s disease-type dementia. In addition, a systematic review that identified randomised placebo-controlled trials investigating the effects of curcumin supplementation on cognitive function in older people over the age of 50 years showed significant improvements in three out of five studies.11 A placebo-controlled double-blind randomised controlled trial that was conducted recently in the USA indicated that the use of a highly absorbable oral curcumin (Theracurmin) prevented cognitive decline in people with MCI.12 However, the effects of curcumin have not yet been studied in Japanese population.

Curcumin is a principal component of natural turmeric. Curcumin is the main component of the natural herbal medicine turmeric. It is an antioxidant with anti-inflammatory and anti-amyloid effects.6 7 It is used as a health food in Japan, as a spice and colouring agent in food in India, as an herbal medicine in China and as a widely used safe colouring agent in the USA. If methods of using inexpensive, natural products to prevent cognitive decline are widely adopted in the future, it may help countries have a healthy, long-living population.

**Benefit/risk assessment**

MCI is an important risk factor for dementia. Dementia can develop despite the absence of obvious symptoms of cognitive decline. A systematic review suggests that curcumin provides a promising strategy for promoting cognitive function11; however, effective methods of prevention are currently unknown, resulting in unmet needs. Clinical trials using highly absorbable curcumin have been conducted. The enrolment and the conduct of single-centre trials involving (1) mild COPD (UMIN000009139) and (2) impaired glucose tolerance (UMIN000007361) have been completed, and the findings from both trials have been published.10 11 The enrolment and the conduct of a joint clinical study on hypertensive cardiac hypertrophy (UMIN000014232) with the National Hospital Organization (NHO) network concluded at the end of March 2020. The safety profile of the trial preparation has been shown in these studies. The safety endpoint for the current trial will be determined based on the safety profile of the patients who undertook the trial preparation. Based on non-clinical and clinical data of the trial preparation, patients may benefit from the alleviation of MCI (a prodromal stage of dementia). In order to minimise anticipated adverse events, inclusion criteria, criteria for the modification of the treatment, criteria for discontinuing the trial preparation and a schedule for evaluating safety endpoints will be determined.

**Objective of this trial**

This trial will investigate a newly developed preparation of a highly absorbable oral curcumin. The aim of this trial will be to examine the effects of a highly absorbable oral curcumin (brand name: curcuRouge. curcuRouge is being sold commercially) in members of the general public suspected of having MCI, its effects on blood biomarkers and its safety.

**METHODS AND ANALYSIS**

**Study protocol**

An overview of the proposed study protocol is presented in figure 1. The schedule of enrolment, interventions and assessments is illustrated in table 1.

**Design and sample size**

The current trial will be a single-centre randomised placebo-controlled double-blind parallel group trial. A
placebo-controlled double-blind randomised controlled trial conducted in the USA indicated that highly absorbable oral curcumin (Theracurmin) prevented cognitive decline in people with MCI. While the current trial design is based on that trial, it uses a different oral curcumin preparation (brand name: curcuRouge) that is absorbed more readily than Theracurmin. The current trial is being conducted to determine the effects of a highly absorbable oral curcumin (brand name: curcuRouge) on the indicators of cognitive functioning using the scores on the Japanese version of the Mini Mental State Examination (MMSE-J), which is an interview-based measure of cognitive functioning, and blood biomarkers that have been reported to be associated with dementia. The target sample size will be 60 participants (30 taking a placebo and 30 taking the highly absorbable curcumin).

Investigational health food (the trial preparation)
- The trial preparation: a highly absorbable curcumin capsule (curcuRouge) or a placebo capsule (both manufactured and supplied by Therabiopharma).
- The placebo preparation will contain cornstarch instead of curcumin.
- The trial preparation and placebo capsules will have the same external appearance, and their contents are not visible. The hue of the placebo will be adjusted to curcuRouge using food colouring.
- The dosage and method of administration: a 90 mg capsule of highly absorbable curcumin will be taken two times per day (morning and evening).
- The duration of administration: the trial preparation will be taken for 24 weeks.

Appropriateness of the dose
Highly absorbable curcumin (brand name: Theracurmin) is a health food that is sold. Previously, the Kyoto Medical Center conducted single-centre studies in which patients

Table 1 The schedule of enrolment, interventions and assessments

| Characteristics* | X | | | |
|------------------|---|---|---|---|
| Informed consent | X | | | |
| MMSE-J SDS | X | X | X | |
| Confirmation of criteria | X | | | X|
| Registration | X | | | |
| Physical assessments BMI, blood pressure and pulse rate | X | X | X | |
| Clinical assessments† | X | X | X | |
| Serum biomarker‡ | X | | | |
| Treatment | <-------- --------- -------> | | | |
| Monitoring of adverse events | <-------- --------- -------> | | | |
| Monitoring of treatment compliance | X | | | |
| Final assessment | | | | X |

*Characteristics: age, sex, educational background, lifestyle histories (alcohol, smoking), medical histories (eg, cardiovascular diseases, chronic obstructive pulmonary diseases, cancers, controlled hypertension, dyslipidaemia, diabetes, hyperuricaemia), histories of allergies.
†Clinical assessments: biochemical tests in blood and urine for monitoring of adverse events. Red cell counts; haemoglobin level; haematocrit; white cell counts, differential leucocyte counts; platelet counts; and levels of total protein, albumin, total bilirubin, alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, creatinine, urea, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein cholesterol, glucose, triglyceride, and C reactive protein. The biochemical data of the past 3 months are available.
‡Serum biomarkers: soluble lectin-like oxidised LDL receptor-1 (LOX-1), LOX-1 index (soluble LOX1×LOX-1 ligands containing apolipoprotein B), apolipoprotein A1, transthyretin, and C3 are measured by PreMedica, Japan. Serum amyloid A-LDL, α1-antitrypsin-LDL and proinflammatory cytokines (IL-6, IL-1β, IL-10, TNF-α, leptin, adiponectin) are measured by Health Science Research Institute West Japan, Co, Japan. The soluble fragment of triggering receptor expressed on myeloid cells 2 is measured in Kyoto Medical Center, Japan.
BMI, body mass index; IL, interleukin; MMSE-J, Japanese version of the Mini Mental State Examination; SDS, Self-rating Depression Scale; TNF-α, tumour necrosis factor α.
with mild COPD or impaired glucose tolerance were administered Theracurmin 180mg/day or a placebo for 24 weeks. In a mild COPD study, the patients’ age was 70±6 years in the placebo group and 70±7 years in the Theracurmin group. In an impaired glucose tolerance study, the patients’ age was 69±7 years in the placebo group and 70±6 years in the Theracurmin group. The results indicated the safety and efficacy of Theracurmin in patients with mild COPD or impaired glucose tolerance, as described in previous papers. A multicentre clinical study involving patients with hypertensive cardiac hypertrophies was conducted jointly with the NHO network. In that study, the participants were provided Theracurmin 180mg/day for 24 weeks or a placebo as a control. Based on the results of these studies, Theracurmin 180mg/day for 24 weeks is considered safe and efficacious. In addition, a study of excessive intake, in which Theracurmin 900mg/day was ingested for 4 weeks, showed that Theracurmin is clinically safe. curcuRouge is more readily absorbed than Theracurmin, with an area under the receiver operating characteristic curve of 3.4 times and a C\text{max} 5.4 times that of Theracurmin. curcuRouge came to the market in September 2020. According to the Codex Alimentarius Commission, the acceptable daily intake of curcumin is 3mg/kg (180mg/day for an individual weighing 60kg). Based on the results of the previous studies on excessive intake of Theracurmin, taking curcuRouge at 180mg/day is considered to be safe.

**Participants**

The study’s inclusion and exclusion criteria are listed in box 1. The participants will meet all of the inclusion criteria. Individuals who meet any of the exclusion criteria will be excluded.

**Concomitant therapy**

This clinical trial will include members of the general public and not patients. However, an outpatient whose condition is stable can become a potential participant even if they are taking medications other than medication for dementia, which can be used concomitantly. However, the potential participant must have been using that medication for over 6 months prior to the date of consent, and there must have been no change in the regular medication or its dose for the 6 months prior to the date of consent. In principle, the basic treatment will not be modified or added for the duration of the trial. Nevertheless, participants who take oral steroids for a week or longer during the trial period will be excluded from this trial.

**Prohibited concomitant medication/therapy**

Concomitant medication will not be prohibited specifically except for antibiotics, oral steroids, multiple antiplatelet drugs or antithrombotic agents, as listed in the exclusion criteria. In principle, the dosing and dose of the concomitant medications will not be modified for the duration of the trial. If the dosage or dose of concomitant medication is modified due to a medical necessity or if a new medication is required to be administered, the reason, name of the medication, dose and duration of administration will be listed in detail on the survey form (this provision does not apply in the event of a change in the warfarin dose or if an antibiotic or an analgesic is prescribed temporarily (for less than 2 weeks) to treat an acute case of a mild illness).

**Discontinuation criteria**

In the event of any of the occurrence of any of the following, the participants will cease taking the trial preparation:

- Adverse events.
- Discontinuation due to physician’s decisions.
- Pregnancy.
- Protocol violations.
- Discontinuation by the participant.

---

**Box 1 Inclusion and exclusion criteria**

**Inclusion criteria**

‘People who are worried about forgetting things’ will be recruited via posters or websites and interviewed using the Japanese version of the Mini Mental State Examination (MMSE-J) and a Self-rating Depression Scale (SDS). Members of the general public who meet all of the following criteria will serve as participants:

1. MMSE-J: scores between 24 and 27 points (mild cognitive impairment suspected).
2. SDS: scores between 23 and 47 points (normal range).
3. Individuals aged 50 years or over, regardless of sex.
4. Individuals from whom voluntary consent can be obtained in writing.

If an individual who is taking a medication for a condition other than dementia (such as a lifestyle-related disease) is recruited, he or she will be enrolled if he or she is active and his or her condition is stable.

**Exclusion criteria**

Individuals:

- Who regularly consume health foods containing curcumin.
- Who are allergic to curcumin.
- Who are pregnant or breast feeding.
- Taking medication for or receiving outpatient treatment for dementia.
- Being treated for malignancy.
- Taking an antibiotic or a steroid regularly.
- Taking two or more antplatelet drugs or an antplatelet drug and another antithrombotic agent (anticoagulant, eicosapentaenoic acid or prostacyclin).
- With histories of cerebral haemorrhages who are taking antplatelet drugs.
- Receiving oxygen therapy at home.
- On dialysis for renal failure.
- With severe liver dysfunction or cirrhosis.
- With severe cardiac dysfunction.
- Otherwise deemed ineligible for participation in this trial by a principal investigator or sub-investigator.

---

**Definition of stable condition:**

1. Performance Status: 0 or 1
2. Individual aged 50 years or over, regardless of sex.
3. No history of hospitalisation for 1 year prior to the date of consent.
4. MMSE-J: scores between 23 and 47 points (normal range).
5. SDS: scores between 24 and 27 points (mild cognitive impairment suspected).

**Participants**

The study’s inclusion and exclusion criteria are listed in box 1. The participants will meet all of the inclusion criteria. Individuals who meet any of the exclusion criteria will be excluded.

**Concomitant therapy**

This clinical trial will include members of the general public and not patients. However, an outpatient whose condition is stable can become a potential participant even if they are taking medications other than medication for dementia, which can be used concomitantly. However, the potential participant must have been using that medication for over 6 months prior to the date of consent, and there must have been no change in the regular medication or its dose for the 6 months prior to the date of consent. In principle, the basic treatment will not be modified or added for the duration of the trial. Nevertheless, participants who take oral steroids for a week or longer during the trial period will be excluded from this trial.

**Prohibited concomitant medication/therapy**

Concomitant medication will not be prohibited specifically except for antibiotics, oral steroids, multiple antplatelet drugs or antithrombotic agents, as listed in the exclusion criteria. In principle, the dosing and dose of the concomitant medications will not be modified for the duration of the trial. If the dosage or dose of concomitant medication is modified due to a medical necessity or if a new medication is required to be administered, the reason, name of the medication, dose and duration of administration will be listed in detail on the survey form (this provision does not apply in the event of a change in the warfarin dose or if an antibiotic or an analgesic is prescribed temporarily (for less than 2 weeks) to treat an acute case of a mild illness).

**Discontinuation criteria**

In the event of any of the occurrence of any of the following, the participants will cease taking the trial preparation:

- Adverse events.
- Discontinuation due to physician’s decisions.
- Pregnancy.
- Protocol violations.
- Discontinuation by the participant.
Participants who discontinued only the trial treatment will continue to be followed up during the trial period (refer to the schedule for the type of data to be collected during the follow-up).

**Discontinuation or conclusion of this trial**

In the event of the occurrence of any of the following, the trial will be discontinued:
- Screening failures.
- Death.
- Loss to follow-up.
- Withdrawal due to physician decisions.
- Site terminated by the Institutional Review Board (IRB).
- Trial terminated by the IRB.
- Withdrawal by the participant.

If the trial is not discontinued and the last observation is completed, the trial will be then be considered to be concluded.
- Completed (epoch=follow-up).

**Resumption of the trial treatment**

If a participant’s reason for discontinuing a trial preparation is addressed and a physician deems that the participant can resume taking the trial preparation, the participant will resume taking the trial preparation if no more than 4 weeks have passed since time of discontinuation.

**Ethical approval**

All the procedures performed will be in accordance with the ethical standards of the Institutional and National Research Committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study was approved by the Kyoto Medical Center Ethics Committee (No 20-007).

**Observation and testing schedule**

**Primary endpoint**

The primary endpoint for this trial will be the scores obtained from the MMSE-J (an interview-based measure of cognitive functioning). The MMSE-J will be administered prior to the trial and 12 and 24 weeks after the start of the trial. This trial involved the preparation of a recently developed highly absorbable oral curcumin (brand name: curcuRouge). This trial will determine the effects of curcuRouge in members of the general public having MCI.

**Secondary endpoints**

The secondary endpoints for this trial will be the sTREM2, apolipoprotein A1, transthyretin and C3 levels and the presence of adverse events. This trial will use the aforementioned blood biomarkers that have been reported to be associated with dementia to determine the effects of curcuRouge on members of the general public suspected of having MCI. This trial will also examine the safety of curcuRouge in these people. Blood biomarkers will be measured in a blinded manner. The severity of adverse events will be assessed using the Japanese version of the Common Terminology Criteria for Adverse Events V.4.0.

**Exploratory endpoints**

The exploratory endpoints for this trial will be the levels of the inflammatory and anti-inflammatory cytokines (C reactive protein, interleukin (IL-6), IL-1β, IL-10, Monocyte chemoattractant protein-1, tumour necrosis factor α, leptin, adiponectin, etc), oxidised low-density lipoproteins (LDLs) (the LOX index, AT-LDL, serum amyloid A-LDL, etc), growth factors and their soluble receptors (vascular endothelial growth factor (VEGF), soluble VEGF receptors 2, etc), antibody markers (FLC (Serum Free Light Cgain), nucleophosmin, etc), and results of immunity testing (the T cell count, the ratio of the CD4 T cell count to the CD8 T cell count, the naive T cell count, the ratio of the naive T cell count to the memory T cell count, the CD8+ CD28+ T cell count, B cell count, natural killer cell count and the coefficient of proliferation for T cells). These endpoints will be assessed to examine the effects of curcuRouge on other biomarkers in members of the general public suspected of having MCI.

This trial requires blood samples to measure the biomarkers. Blood will be collected from every participant prior to the trial and at 12 and 24 weeks after the start of the trial, and the serum will be preserved.

The samples remaining after the measurements will be retained by Kyoto Medical Center for 10 years after the completion of this trial. Upon completion of this trial, the names of the samples retained, the site where they are stored, the name of the sample control manager and the details of the consent obtained from participants will be reported to the head of the facility involved. Changes in this information will be reported in a similar manner. Once the period of retention is over, the samples will be discarded accordingly, while protecting personal information.

**Statistical analysis**

**Sample size**

A placebo-controlled double-blind randomised controlled trial that involved people with MCI who took highly absorbable oral curcumin (brand name; Theracurmin 180 mg/day) or a placebo for 18 months was recently conducted in the USA. This study allocated 21 patients in the Theracurmin group and 19 patients in the placebo group. Theracurmin group showed significant improvement in cognitive outcome (Buschke CLTR (Constant Long Term Retrieval(CLTR)) from baseline by 20.3 (p=0.002). The difference of Buschke CLTR at 6 months from baseline was read 18 from the figure in the article and estimated 26 patients/group will need to show statistical significance (α=0.05, power=0.8, two-sided test). The current trial will investigate curcuRouge, which is more readily absorbed than Theracurmin. And assuming that approximately 15% of the potential participants will drop out or be ineligible, 30 participants will...
be needed in each group, thus necessitating a total of 60 patients.

**Blind procedure**

Before the start of the study, a statistician will assign numbers to the high-absorption curcumin and placebo using a random number table and send the allocation result to the allocation manager. The allocation manager or an assistant will label the boxes of the highly absorbent curcumin or placebo with the randomised number and send them to Kyoto Medical Center. The investigator will obtain written informed consent from the subjects and confirm that the subjects meet the entry criteria of the study and do not meet the exclusion criteria. The numbers allocated to high-absorption curcumin and placebo boxes will be unknown to the investigator. The investigator will administer the study food in the order of registration, starting with the smallest number.

**Analysis sets**

In all the evaluations of efficacy, the analysis will be based on the intention-to-treat principle. Regardless of the trial preparation intake, the analysis of the full analysis set (FAS) will be the main analysis and the per-protocol set (PPS) of the reference. Safety will be analysed using a safety analysis set (SAF). The sets will be defined as follows:

- **FAS**: the FAS will be the group of all the enrolled participants. If a serious violation of the trial protocol (failure to obtain consent or a major violation of trial procedures) occurs for a participant, that participant will be excluded.
- **PPS**: the PPS will be the group excluding participants from FAS who failed to meet the inclusion criteria or who meet the exclusion criteria, or who received a prohibited concomitant medication/therapy with respect to the provisions of the trial protocol (such as those regarding the trial treatment or concomitant therapy).
- **SAF**: the SAF will be the group of all enrolled participants, not including those who did not receive the trial treatment.

**Methods of analysis**

The details of the statistical analysis will be finalised before locking the database. A summary of the planned methods of statistical analysis that will be used to analyse the primary and secondary endpoints will be as follows:

The characteristics of the participants in both groups will be described using descriptive statistics, and then the distribution of MMSE-J scores (the primary endpoint) will be determined. In the primary analysis, the per cent of change in the MMSE-J score 24 weeks after the start of trial preparation with respect to the score prior to taking the trial preparation will be analysed, to compare the participants taking highly absorbable curcumin with those taking a placebo. In the secondary analyses, (1) the MMSE-J scores 24 weeks after the start of the trial will be compared with the MMSE-J scores prior to the trial in each group (using a paired t-test), and (2) the MMSE-J scores of the participants taking a placebo and participants taking the highly absorbable curcumin will be analysed to examine the time-dependent changes in those scores prior to the trial and at 12 and 24 weeks after the start of the trial. A two-tailed α level of 5% and two-sided 95% CIs will be used.

In addition, the distribution of blood biomarkers (the secondary endpoints and exploratory endpoints) will be determined in a similar manner, and the primary and secondary analyses described earlier will be performed. All the safety analyses will be performed to ensure the safety of the population. The frequency of the adverse events will be compared in participants taking the placebo and those taking the highly absorbable curcumin, according to the type of adverse event. In addition, a stratified analysis using the participant’s sex, age and MMSE-J score at screening will also be considered. When the number of cases reaches 20, an interim analysis will be performed to determine the validity of the sample size.

**Early termination of this trial**

This trial will be terminated early if any of the following situations occur:

- When it is determined that there are problems with the safety of the trial treatment or the placebo treatment based on serious adverse event reports of this trial or any safety information from sources other than from this trial.
- The completion of this trial will be deemed unlikely for reasons such as delays in participant enrolment or frequent deviations from the trial protocol.

**Patient and public involvement**

- Announce the research on posters or websites, and recruit research subjects.
- In this study, in order to protect the privacy of the subjects, the names, details of the current address, telephone numbers, email addresses, work information and school attendance information of the subjects will not be acquired as case data. Consideration should be given to protecting the privacy of research subjects even when the results of the research are published.
- Patients and the general public are not involved in the design of the study.
- The results of this research will be published at academic conferences or published within 2 years after the end of the research.

**DISCUSSION**

Dementia refers to a condition in which various causes, such as brain diseases or disorders, diminish cognitive functioning and hamper the activities of daily living. Dementia restricts the patient’s autonomy in everyday life and his or her social life, and it can lead to a mentally unstable state, which can greatly affect family members (eg, the burden of caregiving and mental
strait). Alzheimer’s disease-type dementia is the most common type of dementia, accounting for 60%–70% of all cases.16 As the cranial nerves degenerate and parts of the brain become atrophic, the Alzheimer’s disease-type dementia progresses gradually. The Alzheimer’s disease-type dementia is caused by the accumulation of amyloid β protein in the brain, the concentration of which increases with age. The amyloid hypothesis, which involves neuronal degeneration, is persuasive, but is yet to be completely elucidated. The worldwide population of patients with dementia is estimated to reach 76 million by 2030 and 135 million by 2050. According to the Hisayama study, there are an estimated 6 million people aged 65 years or older with dementia in Japan (as of 2020), and about 7 million people (approximately one in five elderly) are predicted to have dementia by 2025.17 The social costs of dementia are also increasing, reaching 3.9 trillion yen in the UK and 17.5–24 trillion yen in the USA. Those costs are estimated to reach about 14.5 trillion yen annually (medical costs: 1.9 trillion yen, long-term care costs: 6.4 trillion yen and informal care costs: 6.2 trillion yen) in Japan.18 Therefore, efforts to deal with dementia will be increasingly important, given the ageing population.

MCI is a state in which the memory diminishes, but not to the extent that it impacts everyday life, as in dementia. Individuals with MCI do not exhibit dementia or normal cognitive functioning. A study19 has reported that between 10% and 15% of individuals with MCI will develop Alzheimer’s disease-type dementia within a year, and about half will develop it within 5 years.20 21 Thus, preventive intervention in the earlier stages of MCI is important to delay its progression to dementia. Nevertheless, a treatment that is effective for inhibiting the progression of MCI to dementia has not yet been established. Lifestyle-related diseases (hypertension, dyslipidaemia, diabetes, etc) are risk factors for MCI; however, at this current point in time, the only recommended treatment is a healthy lifestyle, for example, the management of lifestyle-related diseases and aerobic exercise.

Curcumin inhibited amyloid deposition in animal experiments; therefore, it is expected to be effective in treating Alzheimer’s disease-type dementia. While a placebo-controlled double-blind randomised controlled trial that was recently conducted in the USA indicated that the highly absorbable oral curcumin (Theracurmin) prevented cognitive decline in people with MCI,12 the effects of curcumin have not been studied in Japan; therefore, this current trial will determine these effects. This trial will be a prospective randomised placebo-controlled double-blind parallel group trial to determine the effects of highly absorbable oral curcumin (brand name: curcuRouge) on the cognitive functioning of members of the general public suspected of having MCI. The MMSE is the most frequently used test to assess overall cognitive functioning worldwide.22 The score on the MMSE-J, which is the Japanese version of the MMSE (the contents are the same), will be the primary endpoint of this trial. A study has indicated that the MMSE-J can, like the MMSE, serve as a valid and reliable test with which to screen for dementia.23 In addition, the current trial will provide a preliminary evaluation of the blood biomarkers that have been reported to be associated with dementia as well as the inflammatory and anti-inflammatory cytokines. Curcumin has various physiological actions, such as anti-tumour, anti-amyloid, anti-inflammatory and antioxidant activities. This suggests that curcumin is effective in preventing different problems, including cognitive decline. Curcumin may, thus, contribute to a healthy, long-living population. However, curcumin is difficult to dissolve in water and has low bioabsorbability. Therefore, to enhance the physiological activity of curcumin, it is necessary to increase its absorption rate.16 Therefore, in this study, a highly absorbable curcumin preparation, whose safety has been confirmed, will be used. If an inexpensive, natural substance such as curcumin can prevent the progression of MCI to dementia, it may maintain the quality of life of patients, reduce the burden on their families, and reduce social burdens such as medical and long-term care costs, substantially.

In this research, ‘people who are worried about forgetfulness’ are widely recruited on posters or websites, but on top of that, those who are suspected of having MCI in the MMSE-J test, have a normal range in the Self-rating Depression Scale test and are over 50 years old are the research subjects. There is a possibility that the number of research subjects will be small.

ETHICS AND DISSEMINATION
Ethics approval and consent to participate
Informed written consent was obtained from all the participants. The Ethical Review Board of the NHO Kyoto Medical Center approved the study protocol. The approval number is 20-007 (16 November 2020).

Ethical and safety considerations and any dissemination plan
The data collected during this study belong to the NHO, and any publication or abstract of the study results requires the prior consent of the principal investigator’s institution. The results of this study will be published in a conference presentation or article within 2 years of completion of the study. The collected data will be stored at the principal investigator’s facility for at least 5 years after the completion of the study. Consideration will be given to protecting the privacy of the research subjects when destroying the records.

Trial status
At the time of the submission of this manuscript, the recruitment for this study is ongoing.

Acknowledgements We thank Yuko Iida for the technical assistance.

Contributors The study conception and design were by HW, HY, NS, A, AK, YK, TH and KH, and the data were acquired by KH. The drafting of the manuscript was done by MK and YO, and critical revisions were made by YS, TM and KH. TH contributed to overseeing the design of the study, AK, YK and AI contributed to the design of the
protocol. AK and TH contributed to manufacture and supply of investigational foods. All the authors reviewed and approved the final manuscript.

**Funding** Therabiopharma is a company that develops and markets curcuRouge. An agreement on joint research in relation to this trial was conducted between Therabiopharma and the Kyoto Medical Center. The tested samples of curcuRouge and placebo were provided by Therabiopharma. No award/grant has been received for this study.

**Competing interests** None declared.

**Patient and public involvement** Patients and/or the public were not involved in the design, conduct, or reporting, or dissemination plans of this research.

**Patient consent for publication** Not required.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

**ORCID iD**
Yuka Ozaki http://orcid.org/0000-0001-5672-855X

**REFERENCES**
1. Panza F, D’Introno A, Colacicco AM, et al. Current epidemiology of mild cognitive impairment and other predementia syndromes. *Am J Geriatr Psychiatry* 2005;13:633–44.
2. Statistics Bureau. Ministry of Internal Affairs and Communications JAPAN. Available: https://www.stat.go.jp/data/topics/topi1261.html
3. Livingston G, Sommerlad A, Ongena V, et al. Dementia prevention, intervention, and care. *Lancet* 2017;389:2673–734.
4. Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. *N Engl J Med* 2005;352:2379–88.
5. Rakesh G, Szabo ST, Alexopoulos GS, et al. Strategies for dementia prevention: latest evidence and implications. *Ther Adv Chronic Dis* 2017;8:121–36.
6. Gu Y, Lee H-M, Napolitano N, et al. 4-methoxycarbonyl curcumin: a unique inhibitor of both inflammatory mediators and periodontal inflammation. *Mediators Inflamm* 2013;2013:1–10.
7. Gupta SC, Patchva S, Koh W, et al. Discovery of curcumin, a component of golden spice, and its miraculous biological activities. *Clin Exp Pharmacol Physiol* 2012;39:283–99.
8. Morimoto T, Sunagawa Y, Kawaamura T, et al. The dietary compound curcumin inhibits p300 histone acetyltransferase activity and prevents heart failure in rats. *J Clin Invest* 2005;118:868–78.
9. Patent application -083312, 2015
10. Funamoto M, Sunagawa Y, Katanasaka Y, et al. Highly absorptive curcumin reduces serum atherosclerotic low-density lipoprotein levels in patients with mild COPD. *Int J Chron Obstruct Pulmon Dis* 2016;11:2029–34.
11. Nathan S, Nathan MD, Duane DM. Effect of curcumin on cognitive function: A systematic review of randomized controlled trials. *Explore hypothesis med* 2019;4:1–11.
12. Small GW, Siddarth P, Li Z, et al. Memory and brain amyloid and tau effects of a bioavailable form of curcumin in non-demented adults: a double-blind, placebo-controlled 18-month trial. *Am J Geriatr Psychiatry* 2018;26:266–77.
13. Funamoto M, Shimizu K, Sunagawa Y, et al. Effects of highly absorbable curcumin in patients with impaired glucose tolerance and non-insulin-dependent diabetes mellitus. *J Diabetes Res* 2019;2019:1–7.
14. Takahashi T, Iio S, Takara T. Safety evaluation of Theracurmin® in healthy Japanese adults. —A randomized, double-blind, placebo—controlled parallel—group study. *Jpn Pharmacol Ther* 2019;47:1097–113.
15. Sunagawa Y, Miyazaki Y, Funamoto M, et al. A novel amorphous preparation improved curcumin bioavailability in healthy volunteers: a single-dose, double-blind, two-way crossover study. *J Funct Foods* 2021;81:104443.
16. Responding to the Prevalence of Dementia and the Impairment of Daily Functioning by Dementia in Urban Areas, 2011–2012. Study Report, General Research Project to Deal with Dementia, Grant-in-aid for scientific research from the Ministry of Health, Labour and Welfare
17. A Study on Future Estimates of the Elderly Population with Dementia in Japan. Study report, study chair: Toshiharu Ninomiya, special research project in health and labor sciences, Grant-in-aid for scientific research from the Ministry of health, labour and welfare; 2014.
18. Estimates of the Social Costs of Dementia. *Hints to the best approaches to improve quality of life for patients with dementia and their families*, Keio University, 2015.
19. Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment—beyond controversies, towards a consensus: report of the International working group on mild cognitive impairment. *J Intern Med* 2004;256:240–6.
20. Bowen J, Teri L, Kukull W, et al. Progression to dementia in patients with isolated memory loss. *Lancet* 1997;349:763–5.
21. Petersen RC, Lopez O, Armstrong MJ, et al. Practice guideline update summary: mild cognitive impairment: report of the guideline development, dissemination, and implementation subcommittee of the American academy of neurology. *Neurology* 2018;90:126–35.
22. Folsom MF, Folsom SE, McHugh PR. "Mini-mental state": A practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res* 1975;12:189–98.
23. Sugishita M, Koshizuka Y, Sudou S. The validity and reliability of the Japanese version of the mini-mental state examination (MMSE-J) with the original procedure of the attention and calculation task. *Japanese J Cognitive Neurosci* 2018;20:91–110.